This page explores key research gaps in neurodegenerative diseases, their contribution to disease progression, and therapeutic implications. Amyotrophic Lateral Sclerosis (ALS) shares significant overlap with Frontotemporal Dementia (FTD) and Parkinson's Disease (PD), making cross-disease comparison essential for understanding common mechanisms and developing effective therapies. [@strong2023]
ALS vs FTD vs PD: Knowledge Gap Comparison
Epidemiological Overlap
The three diseases share substantial epidemiological features that inform research priorities:
| Feature | ALS | FTD | PD | |---------|-----|-----|-----| | Prevalence | 5-10/100,000 | 10-20/100,000 | 100-200/100,000 | | Age of Onset | 55-65 years | 45-65 years | 60-70 years | | Genetic Forms | 5-10% familial | 20-40% familial | 10-15% familial | | Common Genes | C9orf72, SOD1, FTD, TARDBP | C9orf72, GRN, MAPT | LRRK2, GBA, SNCA |
[@burrell2016] ALS and FTD represent a disease spectrum, with approximately 15% of ALS patients meeting criteria for FTD and up to 30% showing mild cognitive impairment. [@chen2023] PD overlaps less directly but shares common mechanisms including neuroinflammation, mitochondrial dysfunction, and protein aggregation.
Mechanistic Knowledge Gaps by Disease
Shared Mechanisms (Highest Priority):
Nucleocytoplasmic Transport Defects: Present in ALS (C9orf72, TDP-43), FTD (TDP-43, progranulin), and PD (LRRK2). Gap: understanding whether this is cause or consequence. [@zhang2023]
...
ALS Knowledge Gaps Ranked List
Introduction
This page explores key research gaps in neurodegenerative diseases, their contribution to disease progression, and therapeutic implications. Amyotrophic Lateral Sclerosis (ALS) shares significant overlap with Frontotemporal Dementia (FTD) and Parkinson's Disease (PD), making cross-disease comparison essential for understanding common mechanisms and developing effective therapies. [@strong2023]
ALS vs FTD vs PD: Knowledge Gap Comparison
Epidemiological Overlap
The three diseases share substantial epidemiological features that inform research priorities:
| Feature | ALS | FTD | PD | |---------|-----|-----|-----| | Prevalence | 5-10/100,000 | 10-20/100,000 | 100-200/100,000 | | Age of Onset | 55-65 years | 45-65 years | 60-70 years | | Genetic Forms | 5-10% familial | 20-40% familial | 10-15% familial | | Common Genes | C9orf72, SOD1, FTD, TARDBP | C9orf72, GRN, MAPT | LRRK2, GBA, SNCA |
[@burrell2016] ALS and FTD represent a disease spectrum, with approximately 15% of ALS patients meeting criteria for FTD and up to 30% showing mild cognitive impairment. [@chen2023] PD overlaps less directly but shares common mechanisms including neuroinflammation, mitochondrial dysfunction, and protein aggregation.
Mechanistic Knowledge Gaps by Disease
Shared Mechanisms (Highest Priority):
Nucleocytoplasmic Transport Defects: Present in ALS (C9orf72, TDP-43), FTD (TDP-43, progranulin), and PD (LRRK2). Gap: understanding whether this is cause or consequence. [@zhang2023]
Neuroinflammation: Microglial activation in all three diseases. Gap: understanding beneficial vs harmful activation states and therapeutic targeting. [@gao2022]
Mitochondrial Dysfunction: Common to all three but with different molecular targets. Gap: identifying disease-specific vs common therapeutic approaches.
ALS-Specific Mechanisms:
TDP-43 Pathology: Present in 97% of ALS cases (except SOD1). Gap: understanding aggregation triggers and propagation mechanisms.
RNA Metabolism Dysregulation: Multiple RNA-binding proteins affected (TDP-43, FUS). Gap: identifying which dysregulation is pathogenic vs adaptive.
Selective Motor Neuron Vulnerability: Specific vulnerability of upper and lower motor neurons. Gap: understanding intrinsic vs extrinsic factors.
FTD-Specific Mechanisms:
Tau and TDP-43 Co-pathology: Understanding the interaction between different protein aggregates.
Progranulin haploinsufficiency: How reduced progranulin leads to neurodegeneration.
Behavioural variant specificity: Why frontal lobe functions are preferentially affected.
Lewy body biology: Relationship between aggregation and neurodegeneration.
Dopaminergic neuron specificity: Why SNc neurons are preferentially lost.
Cross-Disease Research Priorities
Comparing knowledge gaps across diseases reveals common priorities:
Biomarker Development: All three diseases lack definitive biomarkers for diagnosis and progression. CSF, blood, and imaging biomarkers are urgently needed for clinical trials.
Disease-Modifying Therapies: No disease-modifying treatments exist for any of the three diseases. Understanding common mechanisms could accelerate therapeutic development.
Genotype-Phenotype Relationships: How different mutations lead to different clinical phenotypes remains poorly understood.
The Scoring Framework
| Dimension | What it measures | 10 = best | |-----------|-----------------|-----------| | Impact if solved | Would solving this gap change treatment? | Dramatically changes clinical practice | | Tractability | Is this answerable with current technology? | Can be answered within 5 years with available tools | | Current effort | Are too few people working on this? | High = underexplored, low = crowded field | | Data availability | Do we have datasets/biobanks/models to study this? | Rich data available |
Master Gap Ranking Table (ALS-Specific)
| Rank | Research Gap | Impact (0-10) | Tractability (0-10) | Effort (0-10) | Data (0-10) | Total | |------|-------------|----------------|---------------------|---------------|-------------|-----------| | 1 | What triggers sporadic ALS? | 10 | 6 | 8 | 7 | 31 | | 2 | What is the relationship between [TDP-43](/mechanisms/tdp-43-proteinopathy) and disease progression? | 10 | 7 | 7 | 8 | 32 | | 3 | Why do some patients progress rapidly while others survive decades? | 10 | 7 | 8 | 6 | 31 | | 4 | Can we predict which genetic carriers will develop disease? | 10 | 6 | 8 | 7 | 31 | | 5 | What determines which brain region is affected first? | 9 | 7 | 8 | 6 | 30 | | 6 | Why does [C9orf72](/genes/c9orf72) cause both ALS and FTD? | 9 | 7 | 7 | 8 | 31 | | 7 | What is the role of non-neuronal cells in disease initiation vs propagation? | 9 | 7 | 7 | 7 | 30 | | 8 | What causes selective vulnerability of motor neurons? | 9 | 7 | 7 | 7 | 30 | | 9 | Why have so many neuroprotective trials failed? | 10 | 6 | 6 | 7 | 29 | | 10 | Is ALS one disease or several with shared symptoms? | 9 | 6 | 8 | 6 | 29 | | 11 | What is the role of the immune system in ALS progression? | 8 | 7 | 7 | 7 | 29 | | 12 | Can we develop reliable ALS biomarkers for clinical trials? | 9 | 7 | 6 | 8 | 30 | | 13 | What is the role of RNA metabolism dysfunction in [FUS](/genes/fus)-ALS? | 8 | 6 | 7 | 7 | 28 | | 14 | How does metabolism/energy failure contribute to ALS? | 8 | 6 | 7 | 6 | 27 | | 15 | Can [SOD1](/genes/sod1) aggregation be prevented in genetic ALS? | 9 | 7 | 6 | 7 | 29 |
Detailed Gap Analysis
Top 5 Priority Gaps
1. What triggers sporadic ALS? (31 points)
Impact (10): Understanding triggers would enable prevention and early intervention
Tractability (6): Challenging - sporadic ALS has no clear genetic cause
Effort (8): Major research focus but still unresolved
Data (7): Large biobanks available but heterogeneity is a challenge
Current Evidence: ~90% of ALS is sporadic. Theories include:
Viral infections (HSV-1, HHV-6)
Environmental toxins
Metabolic dysfunction
Autoimmune mechanisms
Gut microbiome dysbiosis
Research Needed:
Large-scale prospective cohort studies
Multi-omics profiling of pre-symptomatic individuals
Environmental exposure assessment
2. What is the relationship between TDP-43 and disease progression? (32 points)
Impact (10): TDP-43 pathology is present in 97% of ALS cases
Tractability (7): Good models available
Effort (7): Active research area
Data (8): Rich pathology data available
Current Evidence:
TDP-43 aggregates in motor neurons
Correlates with disease progression
Role in RNA metabolism dysfunction
Research Needed:
Understand TDP-43 aggregation mechanisms
Develop TDP-43 targeted therapies
Biomarkers for TDP-43 pathology
3. Why do some patients progress rapidly while others survive decades? (31 points)
Impact (10): Would enable prognostic counseling and personalized care
Tractability (7): Requires longitudinal data
Effort (8): Understudied area
Data (6): Need better longitudinal cohorts
Current Evidence:
Predictors include: age at onset, bulbar onset, cognitive involvement
Some genetic modifiers identified (UNC13A)
Metabolic factors may play a role
Research Needed:
Biomarker development for progression prediction
Understanding modifiers of disease course
Clinical trial enrichment strategies
4. Can we predict which genetic carriers will develop disease? (31 points)
Impact (10): Would enable prevention trials
Tractability (6): Complex multifactorial
Effort (8): Pre-symptomatic testing advancing
Data (7): Family studies available
Current Evidence: The major genetic forms of ALS include:
[C9orf72](/genes/c9orf72): Hexanucleotide repeat expansion (G4C2) causes both ALS and FTD. Penetrance is incomplete (~40-60% by age 80). [@renton2011]
[SOD1](/genes/sod1): Over 150 mutations identified. Variable penetrance and disease course. [@kabashi2010]
[FUS](/genes/fus): Multiple mutations, often associated with early onset. [@kwiatkowski2009]
Research Needed:
Polygenic risk scores
Biomarker-based prediction
Prevention trial design
5. What determines which brain region is affected first? (30 points)
The C9orf72 expansion is the most common genetic cause of ALS and FTD, accounting for approximately 40% of familial ALS and 25% of familial FTD. [@renton2011]
Mechanistic Gaps:
DPR Protein Toxicity: How the dipeptide repeat proteins (poly-GA, poly-GP, poly-PR) cause neurodegeneration remains unclear.
RNA Toxicity: The expanded RNA forms toxic foci that sequester RNA-binding proteins.
Nucleocytoplasmic transport: Both mechanisms impair nuclear import/export. [@zhang2023]
Research Priorities:
Develop DPR-targeted therapeutics
Understand why some carriers develop ALS while others develop FTD
Identify modifiers of age of onset
SOD1 Pathogenesis
SOD1 mutations account for approximately 12-20% of familial ALS. The toxicity of mutant SOD1 is thought to involve:
Aggregate formation
Mitochondrial dysfunction
Oxidative stress
Excitotoxicity
[@kabashi2010]
Research Gaps:
How exactly does mutant SOD1 cause motor neuron death?
Why do different SOD1 mutations have different phenotypes?
Can SOD1 aggregation be prevented or reversed?
Therapeutic Approaches:
Gene silencing (ASO, siRNA)
Small molecule stabilizers
Immunotherapy targeting SOD1
FUS Mutations
FUS (Fused in Sarcoma) mutations cause approximately 5% of familial ALS. Like TDP-43, FUS is an RNA-binding protein involved in RNA processing. [@kwiatkowski2009]
Key Differences from TDP-43-ALS:
FUS aggregates are ubiquitin-negative
Earlier age of onset
More prominent bulbar involvement
Some mutations cause neuronal cytoplasmic inclusions without ALS (FUSopathy)
Research Gaps:
Understanding how FUS mutations cause selective motor neuron vulnerability
Relationship between RNA metabolism dysfunction and aggregation
This section highlights recent publications relevant to ALS knowledge gaps.
[Age and life stage in the experience of amyotrophic lateral sclerosis: a scoping review](https://pubmed.ncbi.nlm.nih.gov/40511793/) (2026 Feb) - Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration - Examines how age and disease stage affect ALS patient experience.
[Mitochondria and the Actin Cytoskeleton in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/41503832/) (2026 Jan) - Cytoskeleton - Reviews mitochondrial-actin interactions in neurodegenerative diseases.
[Neurovascular dynamics in the spinal cord from development to pathophysiology](https://pubmed.ncbi.nlm.nih.gov/41092899/) (2025 Dec) - Neuron - Discusses vascular changes relevant to ALS pathogenesis.
[Leveraging microbiome-based interventions to improve neurodegenerative disease management](https://pubmed.ncbi.nlm.nih.gov/41459056/) (2025) - Frontiers in Nutrition - Reviews microbiota-gut-brain axis interventions.
[Cell-free DNA in ALS diagnostics and prognostics](https://pubmed.ncbi.nlm.nih.gov/41175990/) (2025 Dec) - Neurobiology of Disease - Insights from cancer research applied to ALS.